CNCE Hits A Low, UTHR Throws In The Towel On PAH Drug, ZGNX Plunges On FDA Snub

Today's Daily Dose brings you news about the inter partes review decision on Concert Pharma's patents related to CTP-543; the proposed public offering of Daré Bioscience and Zosano Pharma; United Therapeutics' decision to discontinue the development of a PAH drug and FDA's refusal to review Zogenix' seizure drug candidate FINTEPLA.

from RTT - Biotech http://bit.ly/2I93n6n
via IFTTT